Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
about
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionCurrent challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveLeishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatmentCoating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responsesCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentEfficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label studyDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature.Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report.Novel arylimidamides for treatment of visceral leishmaniasis.Application of nanotechnologies for improved immune response against infectious diseases in the developing worldEfficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trialTreatment of visceral leishmaniasis.Liposomal amphotericin B and leishmaniasis: dose and responseEffectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.An amphotericin B-based drug for treating experimental Leishmania major infection.Naturally occurring culturable aerobic gut flora of adult Phlebotomus papatasi, vector of Leishmania major in the Old World.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.Treatment options for visceral leishmaniasis.Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 studySpecies-directed therapy for leishmaniasis in returning travellers: a comprehensive guideCan we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?Renal involvement in leishmaniasis: a review of the literatureThe economic value of a visceral leishmaniasis vaccine in Bihar state, India.Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.The development and clinical evaluation of second-generation leishmaniasis vaccines.To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).Liposomal amphotericin B as a treatment for human leishmaniasisStrategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.Optimizing efficacy of Amphotericin B through nanomodification.A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India.Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasisTherapeutic options for visceral leishmaniasis.Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment.Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.Neglected tropical diseases: survey and geometry of randomised evidence.
P2860
Q24187699-E96900D2-A474-4938-B3A3-5F1D67C29DACQ28073426-6502359D-E335-4C8C-94B4-758799D8578CQ28082283-91DB4358-EDE0-40BB-BD17-BC96A223F548Q28383050-49EEA24E-5464-447E-9E98-5A9681FF4622Q28475431-F3C9AB19-6825-48CE-98A8-824906BFC6DEQ28543060-EB2EE1E8-932C-4894-93F0-D82CFFE5AC6AQ30275257-74D27210-04EB-4CD0-BE90-1D9355C441BEQ30775480-3814DA5D-5DBD-4FDF-9FE7-DE2674BD9C01Q33603346-FE648C1A-35BA-47F6-BEAF-042EC7F6663FQ33748160-E84802CD-2B80-4E36-9C4F-BCDD92EAE98CQ33876693-AA64D51C-428A-4AA1-976A-5086B83DD66DQ33894321-B2E59A54-A3D0-45FC-B611-CAED718C2E1AQ33898691-AF6F8732-CC70-4514-A054-B5201CA0D150Q33929849-349475F9-1583-474F-8705-327A0D2969D5Q33929854-A43EA7AA-F241-49FE-A56F-278EA9C52CC1Q34024866-7FC4CBA1-7AA2-4BF7-9B66-0D8E454DCB27Q34208797-166098F9-E6C3-4BFC-8560-1C90C6F2B7AEQ34281532-A4030513-DC0F-4A1D-8AA5-7FE0E7E42E4DQ34328882-24B3698D-3974-4CF1-86F7-00A0A6C1938AQ34509079-072BA36F-DCB4-4D91-B2D3-B5CA73790FB5Q34510966-78A44534-39F2-495D-8F37-28FCFC2F30E9Q35012968-CE8B79D1-A18C-4568-894D-161F021678BCQ35150268-575BA99C-5FD4-4C22-A1A2-FF2BC1CAF2B4Q35160905-A0ACB46E-2AC8-45A7-9021-BC045973DBC3Q35494361-A350CEF6-FE1D-4BFB-9A3C-D25C55DA7934Q35574387-0B3B9C3B-38AA-48AB-BE1E-17CB2D7CA131Q35771782-2BD5C922-5278-4FEA-BFEE-869B847F6ECDQ35917392-550F3310-AC23-41FF-BCF2-A192FD8300D4Q35986733-E0532F3F-0F0E-437F-B36C-1346C57C7FCEQ36326798-22FF1C78-2B61-416B-BF97-30617263FEBAQ36456032-E3F741E2-51B7-4AB5-9988-F624613923E2Q36958635-690CEF20-DAFF-4D2B-9A73-EE27FD79D2C1Q37159459-C33036CF-FFF6-4E13-858C-504E2056BC39Q37178176-EA4889D6-1608-4362-BA05-9DE44363D9E0Q37230269-064AFE81-9235-4FE4-9697-ED9D8F6914C6Q37251607-DEA7735F-6FE9-45EF-AB7D-28AB998AE5FEQ37333942-DBAF6FA4-49FD-4F06-BF73-EA0045241A76Q37544514-511C7963-1BDC-4A9C-8BE0-A80000FD93E4Q37773297-BD91F8FD-6A72-4200-9AEE-7C2627CA06D0Q38054293-C067B1CB-5CAA-4D41-BFBB-4D9153600A36
P2860
Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Amphotericin B treatment for I ...... nal versus lipid formulations.
@en
Amphotericin B treatment for I ...... nal versus lipid formulations.
@nl
type
label
Amphotericin B treatment for I ...... nal versus lipid formulations.
@en
Amphotericin B treatment for I ...... nal versus lipid formulations.
@nl
prefLabel
Amphotericin B treatment for I ...... nal versus lipid formulations.
@en
Amphotericin B treatment for I ...... nal versus lipid formulations.
@nl
P2093
P2860
P356
P1476
Amphotericin B treatment for I ...... nal versus lipid formulations.
@en
P2093
A V Suresh
Henry W Murray
Himanshu Mehta
Madhukar Rai
Shri P Singh
P2860
P304
P356
10.1086/380971
P407
P50
P577
2004-01-13T00:00:00Z